Intensity Therapeutics Gets FDA Green Light for Phase 3 Study

By Colin Kellaher

Intensity Therapeutics has received U.S. Food and Drug Administration approval to launch a Phase 3 study of its lead drug candidate INT230-6 in soft tissue sarcoma.

The Shelton, Conn., clinical-stage biotechnology company on Wednesday said it is working with its contracted vendors to initiate the study in the first half of the year.

Intensity said it plans to study INT230-6 as monotherapy compared to standard-of-care drugs in second- and third-line treatment for certain subtypes of soft tissue sarcoma, which are cancers that start in soft tissues and are found mostly in the arms, legs, chest and abdomen.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

01-03-24 0837ET